Hepatitis C: latest news

Hepatitis C resources

Hepatitis C features

Hepatitis C in your own words

Hepatitis C news from aidsmap

More news

Hepatitis C news selected from other sources

  • What We Talk About When We Talk About Hepatitis C

    The cost of treatment is not really the issue. What we are really talking about when we talk about hep C is prejudice. Hepatitis C's association with drug use makes it easy to discriminate against those who have this disease.

    18 September 2015 | Huffington Post
  • More than 200,000 Brits chronically infected with HCV

    Around 214,000 individuals are chronically infected with hepatitis C (HCV) in the UK, national estimates from Public Health England (PHE) suggest.

    02 September 2015 | Nursing in Practice
  • New data shows relentless rise in hepatitis deaths

    World leaders meet in Scotland to discuss urgent response and move towards elimination of 7th biggest global killer. Worldwide, viral hepatitis kills more than 1.4 million people a year, 4000 people a day, and more than 400 million people are chronically infected with hepatitis B or C.

    02 September 2015 | World Hepatitis Summit press release
  • White House Is Pressed to Help Widen Access to Hepatitis C Drugs via Medicaid

    The advisory council criticized three types of restrictions. Some states cover the new drugs only for patients who have advanced liver disease. Many states require patients to abstain from the use of alcohol or illicit drugs for up to a year before treatment. And some states will not cover the drugs unless they are prescribed by specialists like gastroenterologists or experts on infectious diseases.

    26 August 2015 | New York Times
  • Gilead pills priced at $1,000 a day are found cost-effective

    Health insurers that have been reluctant to cover hepatitis C drugs with list prices of $1,000 a daily dose will face more pressure after a report concluding the medications are “cost-effective” given their benefits.

    14 July 2015 | Bloomberg
  • Leading Canadian researcher calls for inclusion of co-infected people in large HCV clinical trials

    Stephen Shafran from the University of Alberta performed a major review of clinical trials of many DAA-containing HCV therapies used for the treatment of HCV mono-infection as well as HIV-HCV co-infection. Cure rates of HCV are “remarkably similar” in HCV mono-infected and co-infected participants who were treated with the same regimen and who have the same strain (genotype) of HCV.

    07 July 2015 | CATIE
  • US: Hepatitis C Rising -- Especially Among Young People -- and May Be Underestimated

    While hepatitis C has traditionally been predominant among Baby Boomers, the new report shows that HCV incidence is rising fastest among young people. But a recently published related study suggests that formal surveillance methods may grossly underestimate the number of people newly infected with HCV.

    06 July 2015 | HIVandHepatitis.com
  • Public health surveillance system may underestimate cases of acute hepatitis C infection

    A new study suggests massive under reporting may occur within the system set up by the US Centers for Disease Control and Prevention to estimate the incidence of acute hepatitis C virus infection. A research team found that less than 1 percent of a group of acute HCV patients in Massachusetts had been reported to the CDC, largely because required data was either not available or did not meet CDC definitions for acute HCV infection.

    02 July 2015 | Eurekalert Inf Dis
  • NHS accused of delaying access to 'highly tolerable' hepatitis C drugs over cost concerns

    The NHS has been accused by leading health charities of attempting to “severely limit” the introduction of new drugs to treat hepatitis C because they are too expensive – despite the cost of them being cleared by officials.

    17 June 2015 | The Independent
  • NHS England stumps up £190m for hep C therapy

    NHS England has agreed to invest a whopping £190 million this year in new treatments for hepatitis C, so that patients with liver cirrhosis can finally get NHS access to AbbVie’s new interferon-free antiviral regimen as well as Gilead’s Sovaldi and Harvoni, and thus hope for a cure.

    12 June 2015 | Pharma Times
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.